Current Status of Ultra Long-Acting Beta Agonists in Children

Ultra long-acting beta-agonists (ULABAs) have emerged as key therapeutic agents in the management of chronic obstructive pulmonary disease (COPD) and asthma, offering prolonged bronchodilation and symptom control in adults. Their extended duration of action, often exceeding 24 h, reduces the need for frequent dosing, enhancing adherence and simplifying treatment regimens. However, the use of ULABAs in children presents unique challenges, including age-specific pharmacodynamics, safety concerns, and the need for appropriate combination therapies with inhaled corticosteroids. Current research suggests potential benefits in improving lung function and the quality of life, yet robust evidence remains limited. Regulatory guidelines vary, emphasizing the cautious application of ULABAs in children, particularly under 12 years, due to concerns about adverse effects and optimal dosing. Future research should address these gaps, focusing on long-term safety, efficacy, and the role of personalized approaches to optimize asthma outcomes in this vulnerable population.